Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Company Overview

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction. In parallel, Cyclerion is advancing CY6463, a central nervous system-penetrant sGC stimulator, in neurocognitive and neurodegenerative disorders. Both programs are supported by preclinical and early-stage clinical data suggesting potential benefits in modulating cGMP signaling across multiple organ systems. Cyclerion leverages a modular research platform to optimize pharmacokinetic and pharmacodynamic properties for both systemic and brain-targeted therapies.

Founded in May 2018 as a spin-out from Ironwood Pharmaceuticals, Cyclerion is headquartered in Cambridge, Massachusetts, with research collaborations and clinical sites spanning the United States and Europe. The company is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. Cyclerion continues to build on its translational science capabilities to expand its pipeline of sGC-based therapeutics and explore strategic partnerships to advance its programs toward regulatory milestones.

Key Stats

• Today's Range: $2.36 to $2.58
• 50-Day Range: $2.17 to $3.64
• 52-Week Range: $1.27 to $9.47
• Volume: 18,303 shs
• Average Volume: 695,515 shs
• Market Capitalization: $7.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Cyclerion Therapeutics Stock Analysis - MarketRank™

Cyclerion Therapeutics scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cyclerion Therapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cyclerion Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cyclerion Therapeutics is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cyclerion Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.11% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently increased by 62.98%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cyclerion Therapeutics does not currently pay a dividend.

Dividend Growth

Cyclerion Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.11% of the float of Cyclerion Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cyclerion Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cyclerion Therapeutics has recently increased by 62.98%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.45

News Sentiment

Cyclerion Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cyclerion Therapeutics this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for CYCN on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Cyclerion Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cyclerion Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.30% of the stock of Cyclerion Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.62% of the stock of Cyclerion Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CYCN Stock Analysis - Frequently Asked Questions

How have CYCN shares performed this year?

Cyclerion Therapeutics' stock was trading at $3.22 at the beginning of the year. Since then, CYCN stock has decreased by 26.7% and is now trading at $2.36.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.11) earnings per share (EPS) for the quarter. Cyclerion Therapeutics had a negative trailing twelve-month return on equity of 22.63% and a negative net margin of 89.51%.

When did Cyclerion Therapeutics' stock split?

Shares of Cyclerion Therapeutics reverse split before market open on Tuesday, May 16th 2023.The 1-20 reverse split was announced on Tuesday, May 16th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 16th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Cyclerion Therapeutics' major shareholders?

Top institutional shareholders of Cyclerion Therapeutics include Tyndall Capital Partners L P (4.65%).
View institutional ownership trends.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclerion Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), GE Aerospace (GE), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYCN
• CIK: 1755237
• Web: www.cyclerion.com
• Phone: (857) 327-8778
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.06 million
• Net Margins: -89.51%
• Pretax Margin: -89.51%
• Return on Equity: -22.63%
• Return on Assets: -20.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.03
• Quick Ratio: 5.03

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 4.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.27 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 3,340,000
• Free Float: 2,192,000
• Market Cap: $8.18 million
• Optionable: No Data
• Beta: 1.34